Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Cijeli opis

Bibliografski detalji

Glavni autori:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2020-07-01
Serija:	Endocrinology, Diabetes & Metabolism
Teme:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Online pristup:	https://doi.org/10.1002/edm2.159
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!